Latest Infrastructure News

SenSen Networks has reported a strong financial turnaround for the year ended June 2025, posting a 26.5% increase in revenue alongside a return to profitability after previous losses.

Blue Energy Limited has successfully raised $3.2 million through a two-tranche placement, complemented by a proposed $250,000 share purchase plan, to fund drilling and pipeline development in Queensland’s North Bowen Basin.

Bathurst Resources reports a dip in FY25 earnings due to lower coal prices and operational challenges but pushes forward with key development projects Buller and Tenas, targeting production growth from FY29.

EPX Limited reported a robust 17% increase in revenue for FY2025, driven by a surge in recurring revenue and strategic expansion into industrial sectors following the Coda Cloud acquisition.

Murray Cod Australia Limited has reported a remarkable turnaround with a $8.56 million profit for FY25, driven by expanded production capacity and growing export markets. The company’s strategic focus on domestic strength and sustainable growth underpins its rising global profile.

Alpha HPA Limited reported a $32.6 million loss for FY2025 while making significant progress on its HPA First Project Stage 2 and securing $400 million in senior debt financing. The company is capitalizing on growing demand from the semiconductor sector with strong Letters of Intent covering 62% of Stage 2 capacity.

Savannah Goldfields Limited is poised to restart gold production in 2025 at its Georgetown and Agate Creek sites, backed by solid ore reserves and ambitious exploration plans to extend mine life.

Tesoro Gold’s latest metallurgical testwork at the Ternera Gold Deposit reveals over 95% gold recovery using a simple, low-cost cyanide process, reinforcing the project’s economic potential and sustainable water use.

Mesoblast Limited marked a transformative year with FDA approval and commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, driving a 191% jump in cell therapy revenues. The company is now poised to expand its footprint in inflammatory diseases with multiple clinical trials and label extensions underway.

Bapcor Limited reported a modest revenue decline and an 8.4% drop in pro-forma NPAT for FY25 amid significant business simplification and strategic initiatives aimed at sustainable growth.

Mesoblast reports a strong FY2025 financial performance driven by the commercial launch of Ryoncil, the first FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease in children. The company is advancing multiple clinical programs targeting inflammatory diseases, heart failure, and chronic low back pain.

Bapcor Limited reported a 117% jump in statutory net profit after tax for FY25, driven by lower significant items despite a slight revenue decline. The company’s strategic reset, including store consolidations and IT upgrades, sets the stage for renewed growth.